title: Captopril and telmisartan treatments attenuate cadmium-induced testicular toxicity in rats.
abstract: The possible protective effect of captopril, an angiotensin-converting enzyme inhibitor, vs. telmisartan, an angiotensin II-receptor antagonist, was investigated in rats with testicular injury induced by a single i.p. injection of cadmium chloride (2 mg/kg). Captopril (60 mg/kg/day, p.o.) and telmisartan (10 mg/kg/day, p.o.) were given for five consecutive days, starting 3 days before cadmium administration. Both agents significantly increased serum testosterone level, which was reduced by cadmium, suppressed lipid peroxidation, restored the depleted reduced glutathione, decreased the elevations of nitric oxide, tumor necrosis factor-α, and cadmium ion levels, and attenuated the reductions of selenium and zinc ions in testicular tissue resulted from cadmium administration. Immunohistochemical analysis revealed that both captopril and telmisartan significantly reduced the cadmium-induced expression of inducible nitric oxide synthase, nuclear factor-κB, Fas ligand, and caspase-3 in testicular tissue. The differences between the results obtained with captopril and telmisartan were insignificant, suggesting that both drugs equally protected the testicular tissue from the detrimental effects of cadmium.
authors.affiliation: Department of Biomedical Sciences, Pharmacology Division, College of Medicine, King Faisal University, Al-Ahsa, Saudi Arabia. amrfouad65@yahoo.com
authors.forename: Amr A
authors.initials: AA
authors.lastname: Fouad
authors.forename: Iyad
authors.initials: I
authors.lastname: Jresat
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology*; D001565:Benzoates / Q000494:pharmacology*; D002104:Cadmium / Q000009:adverse effects / Q000378:metabolism; D019256:Cadmium Chloride / Q000008:administration & dosage / Q000633:toxicity; D002105:Cadmium Poisoning / Q000188:drug therapy*; D002216:Captopril / Q000494:pharmacology*; D053148:Caspase 3 / Q000378:metabolism; D053222:Fas Ligand Protein / Q000378:metabolism; D005978:Glutathione / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D016328:NF-kappa B / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D012643:Selenium / Q000378:metabolism; D000077333:Telmisartan; D013733:Testicular Diseases / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D013737:Testis / Q000187:drug effects / Q000378:metabolism; D013739:Testosterone / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D015032:Zinc / Q000378:metabolism
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D001562:Benzimidazoles; D001565:Benzoates; D053222:Fas Ligand Protein; D016328:NF-kappa B; D014409:Tumor Necrosis Factor-alpha; D002104:Cadmium; D009569:Nitric Oxide; D013739:Testosterone; D002216:Captopril; D052247:Nitric Oxide Synthase Type II; D053148:Caspase 3; D005978:Glutathione; D012643:Selenium; D015032:Zinc; D019256:Cadmium Chloride; D000077333:Telmisartan